Abstract. Alzheimer's disease (AD) is the most common type of dementia with its pathology considered to be the result of complex interactions between genetic and environmental factors. Amongst a large variety of genes analysed, the APO epsilon genotype, represents the only firmly established common genetic risk factor for dementia, with the APO4 carriers being at 3-16 fold increased risk of AD. Although, the mechanisms by which APO genotype impacts on AD progression are not fully understood, recent evidence suggests that a large component of the increased risk associated with an APO4 genotype is likely to be due to increased neuroinflammation and the subsequent loss of cognitive functions. There is increasing evidence from human epidemiological and rodent studies that the consumption of flavonoid-rich foods and n-3 polyunsaturated fatty acids can beneficially influence normal cognitive function. Investigation of the underlying physiological and molecular mechanisms indicates a positive impact of these dietary components on neurogenesis and neuroinflammation. This review will summarise the evidence of the impact and mechanisms underlying the impact of APO genotype on dementia and AD and the potential role of dietary flavonoids and n-3 polyunsaturated fatty in modulating neuroinflammation and neurocognitive performances. Examination of molecular targets is suggestive that increased intakes of these dietary components have the potential alone or in an additive fashion to ameliorate the pathological consequences of the APO4 allele. However research examining the ability of dietary strategies in this large population genotype subgroup is distinctly lacking.
Introduction
Alzheimer's disease (AD) is the most common type of dementia and a significant cause of disability in the elderly. In the latest World Alzheimer Report, Alzheimer's disease International estimated that there are 35.6 million people (2010) worldwide living with dementia which is predicted to increase to 65.7 million by 2030 and 115.4 million by 2050. AD is characterised by a progressive impairment of memory and other cognitive skills leading to dementia. The major pathogenic factors associated with AD include extracellular accumulation of amyloid-beta peptide (A␤) oligomers, intracellular aggregates of the protein Tau, and the loss of cholinergic forebrain innervation. Neuroinflammation is being increasingly recognised for its overall role in AD pathology including the acceleration of neuronal loss and protein deposition. In most cases, neuroinflammation constitutes a beneficial process involved in the maintenance of organ homeostasis and brain resolution in response to infection or injury [1] . However, sustained neuroinflammatory processes may contribute to the cascade of events leading to the progressive neuronal damage observed in AD [2] .
The life long risk of developing AD and age of onset has a large genetic component. Amongst a large variety of potential genetic targets, the apolipoprotein epsilon genotype (APO) represents the only firmly established common genetic risk factor for dementia. APO4 carriers are at 3-16 fold increased risk of AD with a 10 y earlier age of onset [3, 4] . The 'importance' of the APO4 as an AD risk factor is highlighted by the fact that >60% of AD patients are carriers of the APO4 allele even though it is only present in approximately 25% of general Caucasian populations. The mechanisms by which APO genotype impacts on AD pathophysiology is not fully understood but its relatively moderate effect on the plasma lipid profile is unlikely to be the sole explanation for the genotype-mediated increases in disease risk. Recently, the immuno-modulatory and inflammation modulatory properties of the apoE protein have been recognised and shown to be altered in an isoform dependent manner. Such findings may help to explain the significantly increased AD risk in APO4 carriers.
Human epidemiological evidence, randomised controlled trials (RCTs) and cell and animal studies indicate that physiological concentrations of dietary flavonoids and long chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) are able to exert neuroprotective actions, through their interactions with critical neuronal/glial intracellular signaling pathways pivotal in controlling neuronal resistance to neurotoxins (including oxidants ("indirect" antioxidant nature) and inflammatory mediators), and subsequent impact on neuronal differentiation, long-term potentiation and memory [5] [6] [7] [8] .
The aim of this review is to summarise the existing evidence on the APO4-AD associations and on the beneficial effects of flavonoids and n-3 polyunsaturated fatty acids on neurocognitive performances in humans and rodent models. A particular focus will be the impact of APO genotype and flavonoids/LC n-3 PUFA on neuroinflammation and cell signalling pathways, with identified molecular targets strongly suggesting that these dietary components may be effective at counteracting the pathological consequence of the APO4 allele.
Neuroinflammation as a hallmark of Alzheimer's disease pathology
Emerging evidence is demonstrating the central role of neuroinflammation in 'healthy brain ageing' and risk of dementia and AD [9, 10] . Neuroinflammation is 'driven' by activated resident glial cells (astrocytes and microglia) which result in invasion of circulating immune cells and the production of pro-inflammatory, cytokines (TNF-␣, IL-1␤, IL-6), nitric oxide (NO), prostaglandin E2, chemokines, and reactive oxygen species (ROS). Several findings support the role of neuroinflammation in the pathogenesis of AD. In post-mortem brain tissues from AD patients, activated microglial cells surrounding amyloid-␤ plaques (A␤ or senile plaque, one of the defining pathological features of AD) and increased levels of cytokines have been reported [11] . Long term use of non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to lower the risk of AD in later life [12] . Furthermore, gene variants of several inflammatory cytokines and their receptors [13] have been shown to modulate AD risk and studies with transgenic animal models of AD demonstrate that inflammation is a key component of AD pathogenesis. Markers of inflammation in microglia and astrocytes are significantly increased in the hippocampus of both aged animals and humans [14, 15] . For example, microglial cells isolated from aged mice's brains have increased basal levels of proinflammatory cytokines, which could exacerbate cognitive deficits associated with neuroinflammation [16] .
A potential mechanism by which neuroinflammation may hinder memory during normal or pathological aging is believed to be linked to alterations in neurogenesis. In support of this statement, it has recently been suggested that pro-inflammatory cytokines may contribute to the anti-neurogenic effect by suppressing hippocampal neurogenesis in the aging brain [15, 17] . The reasons for decreased neurogenesis with aging may be related to an intrinsic inability to respond to the proliferative stimulation in the neurogenic niche, a reduction of proliferative stem cells number, activated microglia and neuroinflammation [18] .
Although substantial evidence suggests that chronic inflammation in the CNS may contribute to neuronal dysfunction and loss, the exact molecular mechanisms involved in inflammatory-induced neuronal death and overall AD pathology remain unclear. Emerging evidence suggests that regulation of signal transduction pathways, such as the mitogen activated protein kinase (MAPK) signalling pathway, play an important role in activated glial-induced neuronal death. MAP kinases, which include extracellular signal-regulated kinase (ERK1/2), c-Jun N-terminal kinase (JNK1/2/3), and p38 kinase (p38 ␣/␤/␥/␦), are important in the transduction of extracellular signals into cellular responses. When activated, these kinases phosphorylate both cytosolic and nuclear target proteins resulting in the activation of transcription factors and ultimately the regulation of gene expression [19] . Both p38 and JNK have been reported to mediate activated gliainduced neuronal death [20, 21] . MAPK signalling has been shown to regulate the activation of iNOS and subsequent NO • production and cytokine release in glial cells. Downstream of the MAP kinase signalling activation in glial cells, various transcription factors including the nuclear transcription factor B (NF-B), the activator protein-1 (AP-1) and the signal transducer and activator of transcription-1 (STAT-1) have been shown to be involved in pro-inflammatory responses in astrocytes and microglia [22] [23] [24] [25] [26] [27] [28] [29] . Of these transcription factors, NF-B can be activated by a wide range of oxidative and pro-inflammatory stimuli and is mainly controlled by elements of the MAPK signalling pathways that are activated during neuroinflammation. For example, ERK has little effect on NF-B activation or iNOS induction in astrocytes [30, 31] , whilst p38 and JNK promote NF-B and iNOS activation in both astrocytes and microglia [32, 33] . NF-B activation is observed in a number of neurodegenerative disorders. For example, in studies of post-mortem AD patients, neurons and astrocytes in the vicinity of ␤-amyloid plaques show increased NF-B immunoreactivity [34] . Upon activation, NF-B influences the expression of a complex array of genes which serve important functions in cellular responses to injury and in neuronal plasticity. Amongst these genes, several injury-responsive cytokines, including TNF-␣ and IL-6, are produced in particularly high amounts by microglia and astrocytes [35] . Interestingly, although enhanced NF-B activity is strongly associated with neurodegeneration, its activity is essential for astrocyte and microglial survival [36, 37] .
APOE genotype in neuroinflammation and cognitive decline
Amongst a large variety of gene variants analysed, the APO genotype is the most significant common genetic determinant of risk, age of onset, clinical outcome and rate of progression of a number of neurodegenerative diseases including AD [38, 39] . The APO gene is highly polymorphic, with the epsilon non-synonymous variant yielding three common apoE isoforms, the apoE2 (Cys 112 Cys 158), apoE3 (Cys 112 Arg 158), and apoE4 (Arg 112 Arg 158) mature proteins [40] . Approximately 55-60% of Caucasians are homozygous for the 3 allele (3/3), with 12-15% being 2 carriers (2/2, 2/3) and the remaining 25-27% being either heterozygous or homozygous for the APO4 isoform (3/4, 4/4) [41] . Based on replication in a large number of human association studies, predominately using a candidate gene approach and over the last 5 years, genome wide analysis studies (GWAS), have firmly established the 4 allele of APO as a susceptibility factor for AD [42] . Output from the AlzGene database (www.alzgene.org), which includes data from 1395 independent studies, exemplifies the highly clinical significant impact of APO genotype on AD risk, with relative risks (RR) of 3 and 12-15 in APO3/4 and APO4/4 individuals relative to the wild-type APO3/3 genotype [3] . The importance of APO genotype in cognitive health is further evidenced by the fact that >60% of AD sufferers are APO4 carriers relative to 25-27% in the general population. Furthermore in healthy aging populations an APO4 genotype is associated with poorer cognitive performance [43] , a more rapid decline in cognitive function [44] , higher conversion rates of mild cognitive impairment (MCI) to AD [45] , and an earlier age of AD onset [38] . For example, in "The Cache County Study", carriers of the APO4 allele in the elderly participants (mean age 74 y) had lower baseline cognition and steeper decline in cognition than non-carriers over the 7 y follow up period [44] . These results were further substantiated by another longitudinal study, demonstrating that APO4 status had a significant impact on cognitive and functional decline on multiple measures, including working memory [45] . Animal studies also suggest a strong role of APO genotype in learning and memory [46, 47] with spatial memory being particularly affected in APO4 transgenic mice, [48] .
As the name suggest apoE was originally described as an important modulator of circulating lipoprotein metabolism. The observed modestly higher plasma LDL-cholesterol concentrations (which are thought to in part explain the increase in cardiovascular disease risk reported in those with an APO4 genotype) in APO4 carriers may also contribute to the increased risk of AD. [49, 50] . However emerging evidence is suggestive that a dysregulation of the brain response of activated glial inflammation and oxidative sensitive metabolic pathways in APO4 carriers may in part underlie the increased risk of neurodegenerative disorders in this large population subgroup [51] . In support of this statement, a recent prospective study investigating the effects of both APO genotype and NSAIDs reported a decreased risk in APO4 carriers, with little to no reduction risks among NSAID-using, non-APO4 subjects [52] . These findings further support earlier epidemiologic work by Hayden and collaborators, who also reported a significant AD protective effect of NSAIDs that was most notable in APO4 subjects [53] . Such observations have led scientists to investigate the role of APO-mediated neuroinflammation in animal and cell models.
Several studies have repeatedly reported that exogenously applied APO4 had a higher inflammatory status relative to APO3 in both astrocytes and microglial cells [54, 55] . For example, using cells, transgenic human APO3 and APO4 mice and human models, studies have reported increased inflammatory cytokine production (i.e. TNF-␣ and IL-6) [56] , reduced levels of the anti-inflammatory HO-1 and IL-10, increased NO production [57, 58] , F2-isoprostanes [59] , superoxide concentrations and membrane oxidation, associated with the APO4 allele [60] [61] [62] . Such results were subsequently confirmed by analysing the dose-dependent association of the APO4 allele with innate immune response [63] and cytokine-induced neurotoxicity [64] , therefore suggesting that the cognitive deficits and cortical neuropathology associated with the APO4 allele may be partly due to an impact of genotype on inflammatory mechanisms and subsequent neurogenesis inhibition (Fig. 1) .
The loss of neurons associated with neuroinflammation and brain atrophy, occurs when there is an imbalance between, neuronal apoptosis and loss of dendrite density, and neuronal repair and neurogenesis [15, 17, 18] . Using transgenic knock-in mice and human post-mortem brain tissue, human APO3 and wild-type mice had a higher density of dendritic spines than human APO4 and APO knock-out mice in the 1 and 2 year age group, while at 3 weeks there were no differences between the groups. Significantly in human brain, APO4 dose correlated inversely with dendritic spine density of neuronal cell in the hippocampus of both AD and aged normal controls [65] . Such differences may arise from the fact that neurons developing in APO4 carriers display a mild delay in neuronal maturation, reflected by impairment in dendritic length and complexity, increased membrane resistance and diminished GABAergic interneurons and synapses [66] . The ability of APO4 to promote such disparity has been proposed to be the result of its differential activity (compared to APO2 and APO3) towards glial and neuronal signaling. ApoE has been reported to modulate various signalling pathways in an isoform-specific manner. Indeed, apoE isoforms differentially influence calcium channels causing altered increases in free intracellular calcium [67] . Moreover, apoE isoforms were also observed to affect PKCalpha translocation [68] and to modulate the glycogen synthase kinase-3␤ (GSK-3␤), the protein kinase B (Akt) [69] , the extracellular signal-regulated kinase 1/2 (ERK), c-jun N-terminal kinase 1/2 (JNK) [70] and the transcriptional activity of the cAMP response element-binding protein (CREB) [71] . More recently, Ophir and colleagues demonstrated that the genes that were most differentially expressed in APO4 compared to APO3 were significantly enriched in nuclear factor κB (NFκB) response element [72] . On the other hand, other studies supported the hypothesis that APO genotype-mediated effects in microglia were p38 dependent [64, 73] . The link between APO, signaling and inflammatory outcomes is intriguing, although further work is required to fully understand the molecular mechanisms underlying the differential effects of APO in neurological disorders (Fig. 1). 
Diet, neuroinflammation and cognitive function
The majority of existing drug treatments for AD such as cholinesterase inhibitors and NMDA receptor antagonists do not target the underlying degeneration of neurons, and consequently there is a great need to develop alternative therapies capable of preventing the progressive loss of specific neuronal populations [74, 75] . Various therapeutic approaches that directly or indirectly influence inflammatory responses have/are being developed and tested (see review by Glass et al. [1] ). Recently, much interest has focused on the suggested anti-inflammatory and neuroprotective effects of dietary derived flavonoids and the LC n-3 PUFA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), rendering these molecules as potential candidates for use in preventative and therapeutic strategies to reduce the risk of chronic degenerative diseases development, including AD. The following sections will review the role of flavonoids and n-3 polyunsaturated fatty acids in preventing neuroinflammation and modulating age-related memory decline, and will describe the potential mechanisms of action underlying their neuroprotective effects.
Dietary flavonoids, neuroinflammation and cognitive functions
Dietary intervention studies with flavonoid-rich plant extracts in several mammalian species including humans, have indicated an ability of these dietary components to influence the incidence and onset of neurodegeneration and to counteract age-related cognitive decline [76] [77] [78] [79] [80] . Interventions with Camellia sinensis (tea) [81] [82] [83] [84] [85] , Gingko Biloba [86, 87] , Theobroma cacao (cocoa) [88] [89] [90] and Vaccinium spp (blueberry) [91] [92] [93] [94] , have demonstrated beneficial effects on memory and learning in both animals and humans. For example, the Ginkgo biloba extract EGb761 has been shown to protect rat primary hippocampal neurons against nitric oxide induced damage [95] and to decrease beta-amyloid-induced neurotoxicity in a neuroblastoma cell line stably expressing an AD-associated mutation [96] . Furthermore, green tea catechins improved both reference and working memory, and decreased hippocampal reactive oxygen species in rats [82] . The plant-derived flavanol, (−)-epicatechin, was observed to improve spatial memory retention and to increase angiogenesis and neuronal spine density in the gyrus dentate of treated mice [97] . Interestingly, CNS imaging studies in humans have demonstrated that the consumption of cocoa flavanols (900 mg flavanols daily for 1 week), may enhance cortical blood flow as assessed by transcranial Doppler ultrasound and gadolinium perfusion magnetic resonance imaging [88] . Increased cerebrovascular function, especially in the hippocampus, a brain region important for memory, may facilitate adult neurogenesis. Upon microarray analysis of hippocampal tissue of mice that consumed this compound, expression of genes associated with neurite extension and synaptic plasticity was enhanced [98] .
In vitro mechanistic investigations have started to elucidate the molecular mechanisms by which flavonoids and their metabolites may mediate such behavioural changes. Emanating results suggest that flavonoids, at dietary relevant concentrations, induce neuronal effects by modulating intracellular signalling cascades which are pivotal in sensing, interpreting and ultimately determining the fate of a cell following a toxic insult [5, 6, [99] [100] [101] . For example, green tea catechins [102, 103] and blueberry [92, [104] [105] [106] have been proposed to prevent age-related deficits in memory and learning through their actions on receptors, kinases and transcription factors known to be key in defining hippocampal plasticity and neurogenesis [107] . Furthermore, the enhancement of spatial memory by blueberry flavonoids was paralleled by alterations in signalling pathways known to be involved in long-term potentiation (LTP) and synaptic plasticity the hippocampus [93] .
Since evidence emerged that non-steroidal antiinflammatory drugs may be effective in delaying the onset of neurodegenerative disorders [108] , there has been much interest in the development of new drugs capable of preventing neuroinflammatory mediated brain injury. Although rather complex, the main anti-inflammatory properties of flavonoids include inhibition of NO production, and inhibition of expression of inflammatory cytokines (e.g. TNF-␣, IL-1␤ and MCP-1) and adhesion molecules (e.g. VCAM-I, ICAM-1 and E-selectin) [109, 110] . For example, the citrus flavanone naringenin has recently been found to be highly effective in reducing LPS/IFN-␥-induced glial cell activation and resulting neuronal injury, via an inhibition of p38 and STAT-1, and a reduction in iNOS expression [111] . Flavonoids present in blueberry have also been shown to inhibit NO, IL-1␤ and TNF-␣ production in activated microglia cells [112] , whilst the flavonol quercetin [113] , the flavones wogonin and bacalein from Scutellaria baicalensis [114] , and the flavanols catechin and epigallocatechin gallate (EGCG) [115] have all been shown to attenuate microglia and/or astrocyte mediated neuroinflammation. Their ability to exert such actions, again appear to rely on their ability to directly modulate protein and lipid kinase signalling pathways [6, 99, 116] , pro-inflammatory transcription factors [117] and the downstream regulation of iNOS and cyclooxygenase (COX-2) expression, NO production, cytokine release and NADPH oxidase activation. For example, the flavonol fisetin, a natural chemical found in strawberries, has been shown to inhibit p38 MAP kinase phosphorylation in LPS-stimulated BV-2 microglial cells [118] and the flavone luteolin found in high concentrations in celery and green pepper, inhibits IL-6 production in activated microglia via inhibition of the JNK signalling pathway [24] . Additional mechanisms have been also suggested for the ability of flavonoids to delay the initiation of and/or slow the progression of AD-like pathology, including a potential to inhibit neuronal apoptosis triggered by neurotoxic species (e.g. oxidative stress and neuroinflammation) or to disrupt amyloid ␤ aggregation and to affect the amyloid precursor protein processing through the inhibition of ␤-secretase (BACE-1) and/or activation of ␣-secretase (ADAM10) (See review by Williams et al. [119] ) (Fig. 2) .
A limited body of evidence is suggestive that APO genotype may influence the beneficial effect of flavonoids in relation to dementia and AD. For example, the frequent consumption of fruits and vegetables was associated with a decreased risk of all cause dementia (hazard ratio [HR] 0.72, 95% CI 0.53 to 0.97) especially among non APOE4 carriers [120] . Furthermore, in APO targeted replacement mice, APO3 mice were more responsive to the TNF-alpha lowering properties of dietary quercetin supplementation as compared to APO4 animals. Further work is required to gain an understanding of the physiological and molecular responses to altered flavonoid intake according to APO genotype.
Dietary long chain n-3 PUFA, neuroinflammation and cognitive function
Relative to systemic tissue, the brain is 5-10 fold enriched in DHA, a LC n-3 PUFA found in fish and some marine algae, indicating the essential role of DHA for normal neurological function [121] . In support of this statement, it has been reported that AD patients have significantly lower brain and systemic DHA levels compared to control subjects, with serum cholesteryl ester-DHA levels reported to be progressively reduced with severity of clinical dementia [122] . Numerous prospective epidemiological cohorts such as the Framingham Heart Study (9.1 y follow up) and the SU.VI.MAX Cohort (13 y follow-up) have reported an association between LC n-3 PUFA intake and status, and cognitive function and AD risk [123, 124] . Less consistent findings have emerged from RCTs, with evidence suggesting little benefits of LC n-3 PUFA supplementation in those with pre-existing AD, but some benefits reported in healthy individuals or those with 'very mild' AD [125, 126] . For example, a previous "omega-3" fatty acid clinical trial in Sweden demonstrated a significant reduction in MMSE decline rate in the LC n-3 PUFA treated group compared with the placebo group in a subgroup of patients with a very mild cognitive dysfunction, observed at 6 and 12 months [125] . Furthermore, a Phase III clinical trial of purified DHA from microalgae has been performed in the US. The MIDAS study reported statistically significant improvements with 900 mg/d algal DHA over placebo on the Paired Associates Learning (PAL) test, with nearly double the reduction in errors on the test in the DHA group compared to placebo, therefore demonstrating improvements in learning and episodic memory function over 6 months in older adults with age-related cognitive decline [126] .
Functional studies in rodent models also support improved LC n-3 PUFA and DHA mediated cognitive function, with post-supplementation improvements in performance in the spatial tasks [127] . Indeed, supplementation with DHA was observed to enhance both neuronal differentiation from G-olig2 embryonic stem cells and to improve spatial learning performance in the Morris water maze compared with control wild type littermates [128] . A reduction in brain DHA levels down to 3-5% of the total fatty acids was also associated with poor water-maze learning memory performance [129] , and recovery of brain DHA levels to 8-12% of the total fatty acids led to recovery of water maze learning memory [127] .
Analysis of hippocampal and other brain tissues derived from rodent and post-mortem humans, along with cell culture studies have indicated numerous overlapping structural and physiological 'benefits' underlying these cognitive effects, including; (i) the provision of DHA for membrane synthesis, (ii) an increased dendritic spine formation, neurite outgrowth and neurogenesis [130] , (iii) a reduction in neuroinflammation and inflammatory cytokine production, largely via a down regulation of NF-B [131] . Mechanisms proposed to explain DHA's anti-inflammatory effects, include activation of Akt, mTOR, and p70S6K signaling [132, 133] , and conversion into other derivatives such as cyclopentone neuroprostanes [134] . Recent evidence suggests that much of the benefit of DHA on hippocampal (primary brain region affected in AD) structure and function is likely to be due to neuroprotectin D1 (NPD1), a potent anti-inflammatory lipooxygenase (LOX) DHA oxidation product which inhibits oxidative stress-mediated proinflammatory gene induction and apoptosis in the brain [135] . NPD1 has been observed to inhibit NF-B activation and cyclooxygenase-2 (COX-2) expression in brain following ischemia-reperfusion [136] , while A␤ peptide-induced apoptosis is associated with ERK and p38-NF-B-mediated COX-2 up-regulation [137] . Neuroprotection mediated by NPD1 may further involve components of signaling pathways upstream of NF-B activation and DNAbinding [138] (Fig. 2) .
The presence of the APO4 allele may modify the relationship of LC n-3 PUFA to dementia and AD. For example, in the Alzheimer's Disease Cooperative Study (ADCS), while there was no DHA treatment effect on any outcome measure in the APO4-positive group, patient receiving DHA (2 g/d) in the APOE 4-negative group had a significantly lower decline in mean change in both ADAS-cog and MMSE scores over 18 months [139] . These results further support previous study findings demonstrating a decreased risk of dementia and Alzheimer disease upon frequent consumption of omega-3 rich oils, especially amongst APO4 non carriers [120, 140, 141] . Such genotypic variations may reside in a differential absorption and transport of PUFAs [140] , or to a modification of the effects of fat intake on amyloid beta metabolism [142] . The interaction between dietary fat and APO genotype on risk for dementia or AD therefore warrants further investigation.
Potential additive effects of dietary
flavonoids, and long chain n-3 PUFA, on neuroinflammation and cognitive functions LC n-3 PUFA (in particular DHA) deficiency represents a plausible pathoethiological mechanism for neuropathology associated with cognitive aging and dementia [143] . As highlighted in the previous sections, both LC n-3 PUFA and flavonoid treatments have been reported to exert positive effects on a number of putative mechanisms of age-related decline by regulating cellular and molecular targets that lead to a decreased neuroinflammation and ultimately promote neurogenesis and neurite outgrowth. However, although some overlap in activity may be evident, due to their chemical nature, these compounds often act at different cellular levels. For example, DHA (highly lipophilic) uniquely provides the fatty acid 'building blocks' (40% neuronal membranes) for the new cell membrane synthesis associated with increased the neurogenesis and spine density. On the other hand, flavonoids are strong modulators of the intracellular signalling pathways involved in counteracting agerelated oxidative stress and therefore are likely to reduce the non-specific oxidation of the unsaturated DHA, into a non-active oxidation product (i.e. isoprostanes). Although currently completely unknown, it is speculated that the combined effects of these two dietary components may be more beneficial than either administered in isolation.
Conclusion
With ageing populations, and the exponential increase in AD risk with age, doubling every 5 years (after the age of 60), a 3-fold rise in population prevalence of AD by 2050 is predicted. As highlighted in this review, neuroinflammation is emerging as a key pathological element of age-related loss of cognitive function. Amongst the genetic mediators, APO genotype has been firmly established as a highly clinically significant risk factor for AD, with 60% of AD patients being APO4 carriers. However the mechanisms underlying APO4-AD associations are only partly understood with recent evidence indicating that neuroinflammation may be involved. Understanding of the pathophysiological mechanisms of the APO4 genotype at the molecular levels would greatly contribute to new therapeutic developments. Recently, flavonoids and LC n-3 PUFA have emerged as potential dietary strategies to reduce the population incidence of dementia. However, efficacy in RCT is needed to support the relatively consistent epidemiological and mechanistic evidence. Dietary strategies to counteract the large increased risk in APO4 carriers are unknown and worthy of investigation. Examination of physiological and molecular targets, as conducted in the current review, is suggestive that flavonoids and LC n-3 PUFA alone or in combination may be effective in counteracting the impact of the APO4 allele. In this respect, intervention trials using prospective recruitment of study participants would help to gain a more comprehensive understanding of APO genotype-diet-AD risk associations and to gain a better knowledge of the cellular and molecular mechanisms underpinning such interactions. An effective dietary strategy to delay the onset of disease, in particular in 'high-risk', early-onset APO4 carriers would contribute significantly to morbidity compression in the elderly and increased healthy life expectancy'. Although quantifying the exact impact on total population prevalence of any preventative strategy is difficult, Sloane and co-authors predict that a delay in disease presentation of 5-7 y, would reduce the population incidence by as much as 30-50% [144] . In an era of move to the part replacement of generic population dietary recommendations with personalised/stratified guidance, it is likely that the identification and provision of targeted dietary advice, which could delay or prevent dementia in the large population subgroup of APOε4 carriers, would be would be of considerable societal and economic benefit.
